 

FRONTIER SCIENCE | PUBLICATIONS

APHINITY | AACR Cancer Research

Cancer Research_publication_logo

APHINITY_project_logo_lrg

TITLE OF PUBLICATION

Effect of young age at diagnosis on clinical outcomes and efficacy of anti-HER2 targeted therapy in patients with HER2-positive early breast cancer: Results from the APHINITY trial

Authors

Richard D.Gelber; Xin V.Wang; Bernard F.Cole; David Cameron; Fatima Cardoso; Vivianne Tjan-Heijnen; Ian Krop; Sherene Loi; Roberto Salgado; Astrid Kiermaier; Elizabeth Frank; Debora Fumagalli; Carmela Caballero; Evandro de Azambuja; Marion Procter; Emma Clark; Eleonora Restuccia; Sarah Heeson; Jose Bines; Sibylle Loiblt; Martine Piccart-Gebhart on behalf of the APHINITY Steering Committee and Investigators

PUBLICATION REFERENCES

CANCER RESEARCH | Volume 82 | Issue 4 | Page(s) Supplement | Publication Year 2022

READ FULL PUBLICATION

MORE PUBLICATIONS FROM FRONTIER SCIENCE SCOTLAND

The HERA Trial: Final Analysis Results

The HERA Trial: Final Analysis Results

Feb 16, 2017

An article published in The Lancet shares the results from the final analysis of the HERceptin Adjuvant (HERA) trial.

The NordICC Study: Population-based colonoscopy screening for colorectal cancer: a randomized clinical trial.

The NordICC Study: Population-based colonoscopy screening for colorectal cancer: a randomized clinical trial.

Jul 1, 2016

JAMA Internal Medicine reports on the investigation into participation rates, adenoma yield, performance, and adverse events of population-based colonoscopy screening in several European countries.

The ALTTO Trial: Results of the Primary Analysis

The ALTTO Trial: Results of the Primary Analysis

Apr 1, 2016

An article in the JCO reports that adjuvant treatment that includes lapatinib did not significantly improve Disease-Free Survival compared with trastuzmab alone and added toxicity. One year of adjuvant trastuzumab remains standard of care.

The Neo-ALTTO Trial: Pathological complete response after neoadjuvant anti-HER2 therapy

The Neo-ALTTO Trial: Pathological complete response after neoadjuvant anti-HER2 therapy

Sep 1, 2014

Findings from this study confirm that patients who achieve pathological complete response after neoadjuvant anti-HER2 therapy have longer event-free and overall survival than do patients without pathological complete response.

The HERA Trial: Cardiac Events at 8 years median follow-up

The HERA Trial: Cardiac Events at 8 years median follow-up

Jul 10, 2014

The JCO confirms the low incidence of cardiac events for trastuzumab given sequentially after chemotherapy and radiotherapy.

The Neo-ALTTO Trial: Dual inhibition of HER2 in HER2-positive Breast Cancer

The Neo-ALTTO Trial: Dual inhibition of HER2 in HER2-positive Breast Cancer

Feb 18, 2012

An article in The Lancet reporting that dual inhibition of HER2 might be a valid approach to treatment of HER2-positive breast cancer in the neoadjuvant setting.

The HERA Trial: The Benefits of Trastuzumab by Degree of HER2 amplification

The HERA Trial: The Benefits of Trastuzumab by Degree of HER2 amplification

Jun 20, 2009

An article in the JCO shows that the degree of HER2 amplification does not influence prognosis or benefit from adjuvant trastuzumab in patients treated with prior adjuvant chemotherapy.

The HERA Trial: Adjuvant trastuzumab therapy reduces the risk of relapse across subgroups

The HERA Trial: Adjuvant trastuzumab therapy reduces the risk of relapse across subgroups

Jun 1, 2008

The Annals of Oncology presents the magnitude of trastuzumab effects within patient subgroups in the HERA trial.

The HERA Trial: Results of the First Planned Interim Analysis

The HERA Trial: Results of the First Planned Interim Analysis

Oct 20, 2005

An article in the New England Journal of Medicine reporting on the results of the first, planned interim analysis of the HERA Trial.

Next Entries »